Sign in

    Steven Willey

    Managing Director and Senior Biotechnology Analyst at Stifel

    Stephen Willey is a Managing Director and Senior Biotechnology Analyst at Stifel, specializing in healthcare sector research with a focus on biotechnology companies. He covers high-profile biotech firms and has maintained a recommendation track record with a buy rating success rate of 71%, hold at 29%, and overall analyst ranking near the top 3,000 on independent analyst platforms, with documented strong returns of approximately 7.8%. Willey joined Stifel in 2010 through the acquisition of Thomas Weisel Partners, having previously worked as a research scientist at ImClone Systems and a research associate at Mount Sinai School of Medicine. He holds an undergraduate degree from the University of New Hampshire, an M.S. from the University of Rhode Island, and an MBA from New York University, further supporting his professional standing as an equity analyst.

    Steven Willey's questions to Compass Therapeutics (CMPX) leadership

    Steven Willey's questions to Compass Therapeutics (CMPX) leadership • Q2 2025

    Question

    An analyst on behalf of Steven Willey at Stifel asked about the patient demographics in the Tivesimig trial and the confidence that they reflect historical trial populations, given the lower-than-expected death rate. He also inquired about the preclinical safety data for CTX-10726.

    Answer

    CEO Thomas Schuetz responded that while it's hard to make cross-trial comparisons without the final data, the randomization was stratified by key prognostic variables (performance status, metastatic disease location, anatomic subtype), ensuring the treatment arms should be well-balanced. He confirmed that preclinical data for CTX-10726 will be presented at a scientific conference later in the year.

    Ask Fintool Equity Research AI

    Steven Willey's questions to Compass Therapeutics (CMPX) leadership • Q2 2025

    Question

    An analyst on behalf of Steven Willey at Stifel asked about confidence in the Tivesimig patient population being reflective of historical trials, given the lower-than-expected death rate, and inquired about preclinical safety data for CTX-10726.

    Answer

    CEO Thomas Schuetz addressed the Tivesimig question by highlighting that the study's randomization was stratified by three key prognostic variables, ensuring the treatment arms should be well-balanced. For CTX-10726, he confirmed that preclinical data, including safety, will be presented at a scientific conference later in the year.

    Ask Fintool Equity Research AI